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INTRODUCTION 
A. Hypertens ion 
Hypertension or high blood pressure is a major cause of illness and 
1 2 death in the United States today . ' An estimated thirty-s ix million 
people suffer from this diseas e . 3 Prolonged hypertens ion and its  
at tendant strain on  various organs may cause heart failure ,  brain 
4 st roke or kidney damage . Usually , a pressure of 1 40/90 mm Hg is taken 
to be the d ividing line between normo tension and hypertension. 5 , 6 
The hypertens ive cond i t ion is generally characterized as either 
1 primary ( essent ial) hypertension or seconda ry hype rtension.  A 
spec i f ic cause can be ident i f ied in secondary hype rtens ive patients ,  
such as , pheochromocytoma or adrenal tumor .  These causes can typically 
be correc ted by surgery . Essent ial hypertens ion occurrs in about 90% 
of the hypertens ive populat ion.  The et iology of es sent ial hypertension 
is unknown . 1 , 3 , 6  The increase in dias tolic pressure in primary 
hypertens ion may take on ei ther a gradual (benign) or accelerated 
(malignant ) course . The prognosis  of gradual hype rtens ion i s  more 
favorable than that of the accelerated . Blood pressure in the 
es sential hypertensive patient can almost  always be cont rolled by drug 
therapy . 
It is currently accepted that in mos t  hypertens ive cases the 
primary abnormality is due to a high peripheral resis tance . 7 Numerous 
2 
biological feedback mechanisms interact in trying to re turn the body to 
the normotensive s tate . 8 Some factors involved in  the ma intenance of 
homeostas is  are central and peripheral sympathetic activity , renal 
pressor and depressor mechanisms , antidiure tic hormone , sodium balance ,  
baroreceptors , smal l  blood vessel res istance ,  blood volume and 
1 4 7  viscosity .  ' , 
At temp ts have been made to rationalize the cause of the increase in 
peripheral res i stance in essential hypertens ion as due to either 
humoral or neurogenic factors . 6 , 7  DeQuat tro et al . 9 have clas s i f ied 
the humora l  causes into nephrogenic and steriodogenic agent s .  The 
humoral factors involve the regulation of salt and water content , which 
are mainly under control of the kidneys and adrenal cortex . These 
factors have been impl icated in the sensit ivity of the small  resistive 
arterioles . 1 0  Freis  has sugges ted , based on epidemi ology , the 
exis tance of a cri t ical maximum dietary sodium daily intake of 60 
mmol . 1 1  He found that hypertens ion was common in communi t ies wi th an 
average sodium intake above this level , but on an individual bas i s ,  
b lood pressure has not been correla ted t o  the amount o f  sal t .  
Neurogenic factors have been ci ted because experimental lesions of 
. 1 2  1 3  the central nervous sys tem have produced hypertens10n. ' These 
les ions have resulted in the re set ting of the barostat to a higher 
leve l .  
Many physiological structures are involved i n  the neural regulat ion 
6 o f  blood pressure as can be seen in Figure 1 .  Peripheral vascular 
res i stance , mainly due to arterial contract ion is under the control of 
3 
Figure 1.
6 Phys iological structures involved in neural regulat ion of 
blood pressure. 
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the vasomotor center located in the medulla . This  center is innervated 
from other central areas as we ll  as peripheral baroreceptors . Some 
baroreceptors are located in the carotid  s inus and aortic  arch . An 
i ncrease in arterial pressure as sensed by these baroreceptors causes 
a f f erent tra f f ic  along cranial nerves IX and X, to initiate a decrease 
in the sympa the t ic outflow from the vasomotor centers . Also , there i s  
a n  increase i n  vagal out f low t o  cause a decrease in the heart rate 
which wi ll tend to lower blood pressure . Ef ferent nerve f ibers travel 
down the spinal cord and synapse via connector cells at the sympathet ic 
ganglia .  Stimulation of the postganglionic fibers results  in 
norep inephrine releas e ,  causing vasoconstrict ion through �-adrenergic  
i nteract ion on the arterioles and tachycardia mediated by 
�-adrenoceptors . Stimulat ion of the preganglionic f iber innervat i ng 
the adrenal medulla results  in the release of epinephrine into the 
sys temi c circulation result ing in a general adrenergic response .  The 
sympathe t ic nervous sys tem also exert s  f ine control of renin re lease 
from the kidney via a A-type adrenergi c  receptor . 1 4  
An increase in ei ther cardi ac output or sympathe t ic activi ty will 
cause an apparent increase in plasma volume and pressure in the 
glomerul ar capillaries . In the normal individual , this results  in an 
i ncrease in the glomerular f iltrat ion rate and an increased excret ion 
o f  sodium due to reduced amounts of  the humoral factors , aldos terone 
and ant id iure t ic  hormone (ADH) . 
Sodium reabsorp tion is controlled by the hormone aldosterone which 
i s  released by the adrenal cortex . Aldosterone secret ion is controlled 
5 
by ref lexes init iated by the kidney . Cells  within the kidney detect 
the amount of  sodium in the tubules . A reduct ion in  tubular sodium 
concentrat ion st imulates the secret ion of the protein renin into the 
blood . Renin enz ymat ically cleaves circulat ing angiotens inogen to the 
sma ller polypept ide angiotens in I .  Angiotensin I i s  cleaved to 
ang iotensin II by the converting enzyme . Angiotensin I I  i s  a potent 
s t imulator of  the adrenal cortex , causing it  to secrete aldos terone . 
This results  in the tubular reabsorpt ion of sodium . The sequence can 
be seen in Figure 2 .  
Changes made in sod ium excre t ion mus t  be  accompanied by  changes in 
water excre t ion in order to regulate extracellular volume . As blood 
pressure increases , baroreceptors located in the left atrium are 
s timulated to cause inhibi t ion of the ADH neurons in the hypothalmus . 
Thus , as blood pressure rises in a normotens ive person , a number of 
neurogenic and humoral factors interact to return the pres sure to 
norma l .  In the hypertensive pat ient , a t  least  one o f  these factors i s  
a t  faul t and homeostasis  cannot be  maintained . 
6 
Figure 2 .  Sequence of events leading to an increase in aldosterone 
secretion . 
Liver 
\; 
Angiotensinogen 
Kidney 
Renin 
\V Converting 
Enzyme 
Adrenal Co rtex 
1\ 
I 
Aldosterone 
---->--7 Angiotensin I > Angiotensin II 
7 
B .  Drug Therapy 
Since correc tion of the underlying cause of essent ial hypertension 
is not poss ible at the present t ime , it  has been accepted pract ice to 
1 5  t reat the d isease with ant ihype rtens ive agents .  These drugs help to 
reduce the severity of  the hypertens ive condit ion and i t s  
compl icat ions by act ing upon physiological mechanisms which regulate 
the control o f  blood pressure . 
Ant ihype rtens ive agents can be classif ied into f ive groups based on 
the primary mechanism involved to elicit  an ant ihypertens ive response: 
d iure t ics , d irect-acting vasod ilators , angiotensin analogues ,  
5 7 converting enzyme inhib itors , and sympathetic antagonists . ' 
There are three major classes of diuret ics , the thiaz ide diuret ics , 
the 'loop' diuret ics , and the potassium-sparing agents .  The thiazide 
d iure t ics ( e . g .  chlorothiazide , l) i nterfere w i th the act ive chloride 
reabsorption in the dis tal convoluted segme nt of the renal tubule . 
The 'loop' d iure t ics ( e . g .  furosemide , !) block the act ive t rans port 
of chlor ide ions in the ascending limb of the loop of Henle . The 
potassium-sparing d iuretics  ( e . g . tr iamt erene , 2) cause a decrease in 
the amount of potassium secreted in the dis tal convoluted tubule . 1 
1 2 
3 
D irect-act ing vasodilators produce relaxat ion of the vascular 
smooth muscle . These agents exclude those compounds whose main 
mechanism f or effect i s  med iated by the adrenerg ic nervous sys tem. 
The precise biochemical mechanism for the vasod ilators ,  such as 
hydralazine (�), has no t been elucidated . 16 
4 
8 
9 
The enzymatic conversion of inactive angiotensin I to angiotensin 
I I  is inhibited by converting enzyme inhibitors such as captopril. 
Synthetic analogs, of the potent vasoconstrictor angiotensin I I ,  (e.g. 
saralasin) compete with circulating angiotensin I I  for receptor sites 
within vascular smooth muscle, adrenal cortex and neural tissue.1 
Sympathetic inhibition may occur through a single or a combination 
of four main sites of action: central, ganglionic block, blockade of 
neuroeffector transmission, or adrenergic receptor block. 
Adrenoceptors are classified as �- or �-receptors. 
Ganglionic blocking agents decrease cardiac output as well as total 
17 18 peripheral resistance. ' This occurs by the blockade and the 
displacement of acetylcholine from nicotinic receptor sites 
post junctional to the sympathetic ganglia. Ganglionic blocking drugs, 
such as hexamethonium (�), have severe side effects associated with 
parasympathetic blockade and their use has been superseded by more 
selective agents. 
+ + 
(CH3)3N-(CH2)6-N(CH3
)3 2Cl 
5 
Adrenergic neurone blocking drugs, such as guanethidine (�), 
selectively inhibit the sympathetic nervous system. These agents 
inhibit the release of norepinephrine at the neuroeffector junction. 
1 0  
They are actively taken up and stored within the intraneuronal storage 
vesicles, causing a depletion of norepinephrine. The adrenergic 
neurone blockers are very potent antihypertensive drugs, but 
unfortunately they have many side effects.5 
The main site of antihypertensive action of �-methyldopa (2) is 
within the central nervous system. Alpha-methyldopa crosses the 
blood-brain barrier and is converted to �-methylnorepinephrine within 
the central adrenergic neurons. Stimulation of these central neurons 
results in the release of both norepinephrine and �-methylnorepi-
nephrine. The �-methylnorepinephrine stimulates central 
�-adrenergic receptors causing a decrease in sympathetic efferent 
activity to result in the lowering of arterial pressure.5,6 
7 
1 1  
In res ponse to a decrease in cardiac output by �-adrenergic 
blocking agents, such as propranolol (�), peripheral resistance is 
initially increased . If the fi-blockade is  maintained , cardiac output 
remains at the lowered level and peripheral resistance decreases 
5 result ing in a lowering of blood pressure .  
OH 
, 
o-CH2CHCH2NHCH(CH3)2 
� 
8 
Agent s whi ch block the �-adrenergic receptor also have pe ripheral 
vasodi lator properties . Prazosin (�), a post-synaptic  �-adrenergic 
antagonis t ,  lowers arterial pressure by decreasing peripheral vascular 
res i s tance . 1 9  
9 
The above ant ihyper tensive agents are currently being used in the 
1 5  s tepped treatment o f  hypertens ion.  This  empirical approach has been 
12 
initiated because a speci f ic pathophysiological  abnormal ity is  rarely 
identified in the hypertens ive patient . As the severity of the 
hypertensive disorder increases , a drug from the next step , as shown 
in Figure 3 ,  is added . 
Unf ortunately , none of the agents used are without undes irable s ide 
e f fects . 1 6  Consequently , the search continues for antihypertens ive 
agents with fewer s ide ef fects and with a longer duration of action . 
1 5  
Figure 3. The stepped care approach to ant ihypertensive drugs . 
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C. Mesoionic Compounds 
In 1 935 , Earl and Mackney found that the treatment of 
�-nitroso-�-phenylglycine ClQ, R=C6HS'  R'=H) with acetic anhydride, 
C 20 Ac20) , yielded a neutral anhJdro compound. The structure of the 
14  
stable compound was tentatively proposed by Earl and Mackney to contain 
a three-membered ring fused to a four-membered ring Cll, R=C6HS' R'=H). 
> 
10  
R' 
I 
,.....C-C=O 
R-N,I I 
N-O 
1 1  
This bridged ring, containing a fi-lactone type structure, was 
21 found by Baker et al. to be an unacceptable representation. The 
system as proposed would be highly strained and formation would require 
more drastic conditions than treatment with acetic anhydride. Evidence 
against the strainedfi-lactone type structure includes the fact that 
the compound does not readily decompose with heat. Also, the compound 
as drawn could be optically-active. Compounds made from optically-
active starting material were not optically-active. Electrophilic 
aromatic substitution occurred on the carbon adjacent to the carbonyl 
and not as expected on the benzene nucleus. To account for these 
1 5  
2 1  properties, Baker et al . described the compound as a resonance hybrid 
of a large number of contributing forms . A few of these forms ( 12a-e) 
can be seen in Figure 4 .  The term "mesoionic" was coined to denote the 
contributing dipolar and te trapolar forms . 22 Ollis  and Ramsden in 1 9 76  
sugges t ed that the definit ion include the fact that a sextet o f  
electrons is associated with a f ive- or  s ix-membered ring where the 
ring carries a small  pos i t ive charge and the exocyclic atom or group 
carries the corresponding negat ive charge . Ramsden23 in 1 9 7 9  proposed 
that the term me soionic should be res tricted in its  use to only 
f ive-membered ring systems . 
A s ingle structure, ll, is used to represent these contributing 
resonance forms . Thi s  planar representation i s  incapable of  
optical-activi t y  and the characteristic properties of J.3-lactones are 
not exp ected . The benzene ring is deact ivated toward electrophilic 
sub s t i tution because of  the pos i t ive charge delocalized about the ring . 
R R' 
\ / 
N-C 
/ C\ \ -N � C-O 
"-/ 
o 
1 3  
The mesoionic compound, ll, is  systema tically named a s  a 3-R-4-R' -
1 ,2,3-oxadiazolium-5-o1ate.  This bas ic ring sys tem, the oxadiazole 
Figure 4 .  A few forms contributing to the resonance hybrid structure of 
mesoionic sydnones, 1 2a-e . 
R' 
I 
C=C-O R-N/ I 
�-O 
12a 
R' 
I 
hC-C-O R-t� II 
-"""""N-O - + 
12c 
12e 
R' 
+�C-C=O R-N I 
""'N-O 
12b 
12d 
1 6  
1 7  
with an exocyclic oxygen,  has been given the trivial name "s ydnone . "  
Other nomenclatures can be found in the literature . I t  has been 
sugges ted that the symbol II.!' be used to represent the hybrid structure 
of  mesoionic compounds .  Compound 12 would thus be named as AV-5-ke to-
3-R-4-R' -3 , 5-dihydro-l-oxa-2 , 3-diazole or AV-3-R-4-R'- 1 , 2 , 3-oxadiazole-
5-one . This later nomenclature has been reduced to the trivial name 
4¥ -oxadiazolone . 2 4  Katri tzky has recommended the use  of the betaine 
nomenclat ure . The compound would then be named �h�dro(5-hyd roxy-3-R-
4-R' -I-oxa- 2 , 3-diazolinium hydroxide ) .  
The major thrust  in the investigation of the f ive-membered 
mesoionic compounds has been in the areas of synthesis , s tructural 
. 2 5-32 proof , chemi cal and physical propert1e s .  Excellent reviews are 
' 1 bl 2 2 , 2 3 , 3 3 , 34 ava1 a e .  
Init i al pharmacological investigat ion of mesoionic compounds began 
35  in the early 1 960' s with the report of antitumor activity by  Greco 
and the subsequent report  by Kier et al . 36 of  central nervous sys tem 
s t imulat ion . 
37 The med icinal chemis t ry was reviewed by Ackermann and 
Kier and Roche38 in 1 96 7 . 
The st ructure of the �-alkylsydnones (�, R' =H) , which posses sed 
convulsive act ivity ,  was compared by Kier and Dhawan39 to the 
anticonvulsives 1 5- 1 7 . It was possible to reverse the act ion of the 
anticonvulsives by alkylation of the nit rogen .  The 3 , 4-dialkylsydnones 
40 were also shown to have convuls ive properties . 
4 1  In 1964 , Fregly e t  al . synthesized and investigated three 3-
alkylsydnones for biological act ivi ty . It wa s found that 3-butyl-4-
e thylsydnone (�) had three times the na turetic  and chloruretic ef fect 
R R' 
\ / N- C 
/ \ N 0 c-o-
""0/ 
14 
16 
o 
\\ 
C-NH R, / \ C c=o 
R "" / o 
15 
o 
\\ 
C-NH 
1\1 \ 
C c=o 
Ii "" / N 
H 
17 
of the monoalkylated 3-(sec-butyl)sydnone (�) or the sodium salt of 
3-isopropyl-4-carboxysydnone (�). A dose response curve was obtained 
for the moderate depressor activity of 3-(sec-butyl)sydnone but as the 
dose increased so did the stimulation of the central nervous system. 
The reduction in blood pressure was immediate upon administration to 
normotensive rats but the blood pressure returned to pre-injection 
levels in a matter of minutes. Sodium 3-isopropylsydnone carboxylate 
had no hypotensive activity while 3-butyl-4-ethylsydnone could not be 
tested because of the strong convulsive activity. Greco and Kier42 
18 
synthesized some 3-phenyl-4-acylsydnones, 21. These compounds exhibited 
a moderate hypotensive activity which was greater than that observed for 
3-(sec-butyl)sydnone (�). 
Bu Et 
\ / 
N-C 
/ C\ \ -N � C-O 
�O/ 
1 8  
20 
s-Bu 
- \ 
N-CH 
/ C\ \ -N � c-o 
�O/ 
1 9  
2 1  
4 3  44 Kier et al . ' synthes ized a number of 3-alkyl- 1 , 2 , 3 , 4-oxatri-
azolium-S-olates , 2 2 .  Hypotensive act ivi ty was measured in  the 
anesthet ized dog . Varying the R group , the following order of 
hypotensive activity was observed : .!-Bu > �-Bu '";t 3-pentyl '";t .!.-Pr> 
Et> Me . Pret reatment of the dogs with atropine or pyribenzamine did 
not inf luence the depressor effects of  the �-oxatriazoles , �. The 
3-alkyl-J.!' -oxa t riazoles  appeared to potent iate responses to 
epinephrine .  
1 9  
R 
"N-N 
/ C\ \ -N '(!:; C-O 
""
0
/ 
22 
Kier and Keating45 synthesized �-oxatriazoles with larger 
substituents. The results of some compounds having fair hypotensive 
20 
activity in the anesthetized dog can be seen in Table 1. The onset of 
effect was noted to be within minutes. 
Thomas et al.46 synthesized higher homologs and dimers (bis 
compounds) of the 3-alkyl-1, 2,3,4-oxatriazolium-5-olates. The 
compounds in Table 2 were evaluated for possible hypotensive activity 
in mice and dogs. Active compounds had a rapid onset of action after 
an oral or intravenous administration. Maximum activity was attained 
within thirty minutes. A dose-response curve was obtained for 1-10 
mg/kg whereupon further increases in the dosage did not increase the 
response. These compounds were found to decrease systolic, diastolic 
and pulse pressures. 
21 
4 5  Table 1 .  Blood pressure response and dura tion of ef fect of 3-subs ti-
t uted-l , 2 , 3 , 4-oxatriazolium-5-olates , 2 2 . 
R , 
N-N 
/ C'I \ -N � c-o 
""0 / 
22  
R Dose (mg/kg ) 
CH -CH-CH 2 I 
\ 
N-CH CH-I 3 / 
CH2-CH-CH2 
I 
C
6H5
CH2CHCH3 
CH3-NJ-
(CH3 ) 2CHCH2�HCH3 
I 
(CH3 ) 2NCH2CHCH3 
4-CH3C6114 CHr 
aNo control reported . 
10-50 
10-25  
5-20 
10-50 
50 
50 
% Decrease in 
Blood Pres surea Duration (hr)  
o 0 
( 10-70) 0 . 5  
20-30 1-2 
25-30 1-2  
40-50 3 
25-30 4 . 5  
25  6 
22 
Table 2.46 Percent decrease in blood pressure for 5 mg/kg intravenous 
dose of 3-substituted-l,2,3,4-oxatriazolium-5-o1ates, 22. 
R 
CH2 -yH-CH2"" I N-CH CH-I 1/ CH -CH-CR 2 2 
CH 
CHC 3 CH 3 
N-N-(CH ) -
-o-C, e N 2 6 
' 0/ 
a
No control reported. 
22 
% Decrease in Blood Pressurea 
15-30 
Negligible 
0-15 
Negligible 
Negligible 
15-30 
Negligible 
15-30 
0-15 
0-15 
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The me soionic oxadiazole compound 23a (R=C6H1 1 , R'=mo rpholine) has 
been reported to lower blood pressure in man at low doses by a 
vasodilator mechanism . 4 7  This structure is an analog of compound 23b 
d 48- 5 1  which had been reported earlier to be act ive i n  ogs . The 
activity in spontaneous hypertens ive rats of analogs of the mesoionic 
52 oxadiazole s has been compared . The antihypertensive act ivity of the 
oxad iazole was re tained when the 4-posit ion hydrogen was replaced with 
a halogen . Thi s  act ivity was lost  when the ring hydrogen was replaced 
by a methyl group . 
R' 'N-CH 
! Q \-N�- R 
"'" 'V/ -o 
23 
R 
23a .£-C6Hll 
23b -OC2Hs 
R' 
r---.. 
N 0 '-I 
r---.. 
N 0 
'----.I 
Many inquiries have focused on the synthesis  of drugs which would 
have potent hypotensive act ivity . Investigat ion of the the rapeutic  
potential of  mesoionic compounds is in  its  infancy . 
RESEARCH AIM 
The high incidence of hypertension of unknown etiology and poor 
compl iance us ing exis t ing agents make it de s irable to investigate new 
compounds for hypotensive act ivity . 
The following order of hypotensive act ivi ty was observed in three 
43  > groups of mesoionic compounds : 3-alkyl-A¥-oxatriazole 4-acyl-
24 
s ydnone > 3-alkylsydnone . A correlat ion was found between the increase 
in hypotensive act ivity and the decrease in the charge dens ity on the 
number three nitrogen atom . The calculated charge dens i ty on the 
number three ni trogen atom of 3-phenyl-AY -oxatriazole was found to be 
less  than that of 3-alkyl-�-oxat riazole . 
One goal of this research is to synthesize various substituted aryl 
analogs of  the AV-oxatriazolone system .  Three of the aryl compounds , 
53-57 . 54 5 5  3-phenyl- , 3- ( 4-nlt rophenyl )- , , and the 3-( 4-chloro-
phenyl)_55 , 57 Ap- oxatriazolone have previously been synthes ized . The 
substituted aryl- 1 , 2 , 3 , 4-oxatriazolium-5-olates , 24a-h are seen in 
. 53 57-59 F igure 5 ,  will be prepared accordlng to Scheme 1 .  ' 
The structure of the proposed compounds will  be conf irmed by 
infrared spect ral  analysis , ult raviolet spect ral analysis and carbon , 
hydrogen , and nitrogen analyses .  Integrated carbonyl absorpt ion 
2 5  
inten s i t ies  will be calculated and mass spectra f ragmentation patterns 
investigated . 
I t  is  a purpose of this research to add to the knowledge gained 
f K ·  45  d h 46  rom ler an  T omas by  pharmacologically tes t ing these mesoionic 
compounds for hypotensive act ivi ty . Poss ible vehicles for 
administra t ion of  the mesoionic Ar-oxatriazolones will be examined . 
The LD50 will be es tima ted
60 in the male Sprague-Dawley rat .  A 
dose-response curve will be obtained for 3-( 4-methyl) phenyl-l,2,3,4-
oxatriazolium-5-olate . The t ime course of act ion of the aryl analogs 
will be compared . The various subs ti tuents on the aryl ring will 
provide some informa tion on the s teric and elect ronic requirements for 
activity .  
Figure 5. Substituted 3-aryl-l,2,3,4-oxatriazolium-5-o1ates, �, 
t o  be synthesized . 
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No . R X 
24a H 4 
24b 4-Cl 4 
24c 3,4-Cl2 3 24d 4-NO 4 
24e 4-CH2 4 
24f 4-0C�3 4 24g 4-F 4 
24h 2,6-C1
2 3 
26 
AcOH > 
+ KCN 
> 
26 
( K03S ) 2C=NNHS03K 
28 
> 
Scheme 1.  
> 
25 
27 
+ 
R-C6HXN2 -�!........!:=�-->� R-C6HX-NHN=C( S03K) 2 
29 
24 
27 
28 
RESULTS AND DISCUSSION 
A. Chemi stry 
The synthesis of monopotassium aminomethanedisulfonate (�) was 
ef fec ted by the addition of an aqueous solution of potassium cyanide to 
an aqueous solution of potassium metabisulfite at 55°C as described by 
von Pechmann and Manck . 58 The potassium salts were used for ease of 
isolation .  An infrared spectral band at 3 1 60 cm- 1  indicated the 
+ - 1  p resence of  NH3 group and the broad strong band between 1 260- 1 2 1 0  cm 
was characteris tic of the sulfonate group . 
+ KCN > 
25 
A proposed mechanism for the forma tion of aminomethanedisulfonate 
is seen in Figure 6 .  The hydrogen of the bisul fite ion (25a)  is 
subject to displacement by carbon of the nucleophile , cyanide (25b) . 
Evidence indicates that the hydrogen of the bisulfite ion is bonded to 
61-65 the sulfur  atom ins tead of the oxygen atom .  The resulting 
carbanion , 25c , transposes a hyd rogen ion from another bisulfite ion to 
29 
Figure 6 .  Proposed mechanism for the formation of potassium amino­
methanedi sulf onate.  
0 
I 
O=S-H + C=N: 
I 
0-
2 5a 2 5b 
-
0 0-
I _ I 
O=S-C=NH + H-S=O 
I I 
0- 0-
25c  
25d  
> 
> 
> 
0 
I C=N: -
O-S/ 
I
'H 
0-
-03S" 
- ./ 
O;S, 
0�1 H 
0 
25 
C=NH 
> 
> 
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yield the intermediate 25d. Subsequent acidification results in the 
conversion of excess bisulfite to sulfur dioxide and the precipitation 
of the desired amine salt, 25. 
h 58 T e method of von Pechmann and Manck afforded dipotassium diazo-
methanedisulfonate (�) by pouring cold aqueous potassium nitrite into 
a cold slurry of the previously synthesized amine. By quenching the 
reaction at 45°C high yields of the yellow product were obtained. The 
ultraviolet spectrum and the presence of a diazo band at 2100 cm-1 in 
66 
the infrared spectrum agreed with literature values. 
l03K 
H3�-CH \ 
S03 
25 
+ 
26 
Tetrapotassium sulfohydrazonomethane disulfonic acid (�) was 
prepared in quantitative yield by treating the diazo compound with 
alkaline potassium metabisulfite as described by von Pechmann and 
Manck.58 The structure of � was supported by the lack of the diazo 
band in the infrared spectrum. It was not necessary to isolate this 
white tetrapotassium salt. Treatment of the tetrapotassium slurry with 
concentrated acetic acid to pH 6.5 yielded quantitatively the 
58 
tripotassium sulfohydrazonomethanedisulfonate (28). In the infrared 
-1 spectrum, a band characteristic of N-H stretch was seen at 3340 em • 
N=N=C ( S03K) 2 
26 
27 
+ 
> 
K 
> KO S-N-N=C ( SO K) 3 3 2 
K03S-NH-N=C( S03K) 2 
28 
27 
3 1  
The next s tep involved the coupling o f  the neutral salt , �, to an 
53 aryl diazonium acetate according to the procedure of von Pechmann. 
The use of the neutral salt was preferred over the yellow diazomethane-
57  disulf onate , �, because of  its  greater stability .  
The appropriately substituted , recrystallized or f reshly distil led , 
anilines were diazotized . The pH was adjus ted to 5 by the addition of 
granular potassium acetate. The aryl diazonium acetate ,  lQ, was added 
t o  an aqueous solution of the neutral sal t .  The colored effervescent 
solution was maintained at pH 5 by the addition of granular potassium 
acetate . The desired water-soluble product , �, was isolated by 
concentration in vacuo then precipitation with ethanol . Support for 
the as signed structure was ob tained using infrared spect ral data.  One 
spot was observed on thin layer chromatography . The dry, unsubstituted 
aryl hydrazone was also characterized by the violet color fo rmed on 
t rea tment with concentrated sulfuric acid and ferric chloride as 
53 repor ted by von Pechmann. 
K03S-NH-N=C ( S03K) 2 
28 
+ -----»� R-C6HX-NHN=C ( S03K)2 
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Potassium arylhydrazonomethanedisulfona te (�) was treated with 
potassium nit rite. The water-soluble product which was not isolated 
may be represented as struc ture 3 1 .  The nitroso compound , 1l, was 
added to 2N hydrochloric acid to ef fect cyclization. Fair yields of  
the desired aryl-l , 2 , 3 , 4-oxatriazolium- 5-olates , �, we re obtained. 
The as signed structure was supported by infrared spect ra ,  me lting 
point , elemental analysis and a negative Liebermann nitroso tes t. A 
32 
single spot was seen on TLC. Additional structural support was gained 
on some of the mesoionic compounds using ult raviolet spectra ,  mass 
s pectra and integrated carbonyl absorption intensities. Properties of 
the mesoionic compounds ,  24a-h , are lis ted in Table 3. 
R-C H -N-N=C ( SO K) 6 X I 
3 2 
N=O 
31 
R-C6� 
\ 
N--N 
/ f.\ \ -N \31 c-o 
"'- 0/ 
24 
Thb1e 3 .  Properties of 3-(substituted-aryl)-I,2,3 ,4-0xatr1azoliun-�lates, 24. 
N-C-O 
R-C6� -rf (±) I "N-O 
� 
lit 
IR (CC14) 
no. R X fonw.1a mp
a,oC val % yield anal .  calc (%) fourrl (%) 0=0 (em-I) A ,nn(E.) 
nax 
24a H 4 SHsN302 83-84 89
53 52 1785 215 (7286) 
13355 
265 (9643) 
24b 4-Cl 4 SH4ClNP2 13�136 30 1800 216 (8933) 273 ( 13267) 
24c 3,4-Cl
2 
3 ��Cl2NP2 
1 13-1 16 35 C 36.21 36.32 1805 271 ( 12287) 
H 1 .29 1 .38 
16654 
N 18 . 10 18 .09 
24d 4-002 4 �H4N404 
164-165 25 C 40.38 40.34 1800 
H 1 .92 1 .95 
N 26.92 26 .97 
24e � 4 C8�N302 9&-97 50 C 54.24 53.99 1795 218 (8430) H 3.95 4.04 278 ( 12714) 
N 23.73 23.63 
24f � 4 C8�NP3 13�136 40 C 49.74 49 .76 1790 220 (6929) H 3.63 3.67 305 ( 1 1929) 
N 21 .76 21 .73 
24g 4-F 4 SH4FN302 122-123 33 C 46.41 46.52 1795 220 (8311 )  H 2.21 2.30 295 ( 12147) 
N 23 .21 23. 19 
24h 2,fr{;l2 3 ��Cl2N302 99-100 18 C 36 .21 36.26 1795 
H 1 .29 1 .34 
�rystaJ.lization solvent - metharol. 
N 18 . 10 18 . 1 1  
w 
w 
The fragmentat ion pattern, seen in Figure 7 ,  of 3-phenyl- 1 , 2 , 3 ,4-
oxatriazolium-S-olate in the mass spectrometer was predicted by 
67  Doughery et al . and was similar to that reported by Christophersen 
68 and Treppendahl for  structure 32 . 
32 
Integrated carbonyl absorption intens i t ies for various types of 
34 
carbonyl groups are repor ted in the li terature and can be seen in Table 
4. The integrated carbonyl absorpt ion intensi t ies of the 3-aryl- 1 , 2 , -
3 ,4-oxat riazolium-S-olates were measured according t o  the procedure of 
69 Ramsey . The absorpt ion intens ities of the carbon-oxygen bond were 
found to range from 1 0- 1 2 . 7  indicat ing a high degree of mo lecular 
polarization as is represented by their mesoionic structure. These 
values are reported in Table S .  
Figure 7. Mass spectruu of 3-phenyl-l,2,3,4-oxatriazoliun-5-0late, 24a. 
Table 4 .  Integrated carbonyl absorption intensi t ies . 
Compound 
34  aldehydes , ketones 
es ters34  
3 4  ami des 
34  butyrolactones 
7 0  sydnone 
mesoionic thiazolo[3,2-a]-7 1  pyr imidine-5 , 7-diones 
72  isosydnone 
Absorption Intens ity (A) 
1 . 5-2 . 4  
2 . 5-4 . 1  
3 . 7-5 . 7  
4 . 2  
7 . 0-1 2 . 0  
9 . 9-1 1 . 7 
1 2 . 0- 12 . 5  
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Table 5 .  Integrated carbonyl absorption intens i t ies for 
substituted 3-aryl-l,2,3,4-oxatriazolium-5-olates, 24 . 
R-C6� 
\ 
N-N 
/ Q. \ -N \2:J c-o 
"" 0/ 
24 
37 
R X (Xl0-3 M) Na 
Absorp tiog 
( A) no . cone . Intens ity 
24a H 4 2 3 . 5 6  1 1 2 . 2  
50 . 3 1  4 1 2 . 3  ±C . 2  
24b 4-Cl 4 50 . 6 3  4 1 2 . 48±C . 6 5  
24c 3,4-C12 
3 43 . 7 9  5 1 0 . 2l±0 . 42  
24e 4-CH 4 27 . 5 1  4 1 2 . 96±C . 4 5  3 39 . 30 3 1 2 . 5 9±C . 1 3 
53 . 1 1  4 1 3 .  7l±0 . 28 
24f 4-0CH3 
4 4 1 . 5 5 5 1 1 . 27 ±D . 8 2  
24g 4-F 4 39 . 0 1  5 1 0 .46±Q . 6 2  
a b phenylacetate, lit . val .  3 . 1, No . of observat ions . Contr�� was 
found 3 . 07±0 . 05 at cone . 58 . 7 6xI0 M. 
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B. Pharmacology 
Pre liminary toxicity studies were undertaken to determine the dose 
range to test  for hypotensive act ivity in the male normo tensive 
Sprague-Dawley rat ( 1 7 5-240 g ) .  Dosages ranging f rom 50-500 mg/kg of 
3-( 4-methylphenyl ) - 1 ,2 , 3 , 4-oxatriazolium-5-01ate were adminis tered in 
corn oil by gavage. The animals were cont inually observed during the 
f i rs t  hour ,  hourly for the next eight hours , then every twelve hours 
for 1 4  days. An increase in res pirat ion rate was observed in the four 
rats  dosed above 200 mg/kg. The animal which received 209 mg/kg 
expired after 2. 5 days while the animal dosed at 224 mg/kg survived the 
1 4  day observat ion period. Af ter seven hours , the animal dosed at 360 
mg/kg expired. A rat dosed at 500 mg/kg exhibi ted tonic convuls ions and 
expi red 5 hours af ter receiving the tes t compound. Three animals  
exhibi ted signs of cyanosis  prior to  death. Gross necropsy f indings 
were negat ive. The LDSO was est imated
60 to be 2 1 0  mg/kg. 
Intravenous adminis trat ion of the tes t compounds was precluded by 
their  insuff ic ient solubility in Emulphor , polypropylene glycol 300 , 
and the Tweens 20 , 4 0 ,  and 80. Thus , the oral route of administration 
was chosen to tes t  for hypotens ive activity in the rats using corn oil 
as  the vehicle. 
A femoral artery in a pentobarbital anes thet ized male Sprague­
Dawley rat was cannulated. The blood pressure of the res trained 
anima l ,  upon recovery from anesthesia , was continuously observed for 
one hour prior to the administration of the experimental compound. The 
des i red dose was always dissolved in less  than one mL of corn oil. 
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Blood pressure readings were recorded cont inuously for the f irst  thirty 
minutes af ter oral administrat ion of the tes t compound . In longer 
s tud ies , blood pressure recordings were taken at two hour intervals .  
The experimental parameters , vehicle ,  t ime o f  day o f  blood 
pressure recordings and the length of t ime of unanes thet ized restraint 
did not signi f icantly affect the blood pressure readi ngs . 
Adminis t rat ion of corn oil to three rats  did not af fect their blood 
pressure at thirty minutes . However ,  a mean hypotensive response of 
1 . 7%  was observed in these restrained rats at seven hours . 
A typical hypotensive response for the reference compound , 
clonidine , at a dose of 0 . 1  mg/kg can be seen in Table 6 .  Both 
systolic and diastolic pres sures were depressed equally in two of  the 
f our rats dosed with clonidine .  The maximum hypo tens ive response 
occurred at two hours .  The systolic pressure was quicker to return to 
pre-administra t ion levels . 
The maximum ef fect on the mean arterial blood pressure by varying 
the dose o f  3-( 4-methylphenyl )- 1 , 2 , 3 , 4-oxat riazolium-5-olate is shown 
in Table 7 .  The percent decrease of both the systolic and diastolic 
pressures were equal . The onset of pressure reduct ion was observable 
af ter 2-3 minutes and the maximum ef fect was attained within thirty 
minutes for doses less  than 1 5  mg/kg . For higher doses , the maximum 
ef fect was achieved within one hour . The duration of act ivity was dose 
dependent .  I t  can be seen i n  Table 8 that subs tant ial decreases in 
blood pressures at five hours exist  af ter single doses of 1 5  and 25 
mg/kg of  the 4-methylphenyl analogue. A typical time course for the 
hypotensive response can be seen in Table 9 for  a dose of 1 5  mg/kg of 
Table 6 .  Hypotensibe response of rats
a to the oral administration of 
0 . 1  mg/kg clonidine . c 
a 
Time (hr ) 
0 . 0  
0 . 6  
1 . 5 
2 . 0  
3 . 0  
4 . 0 
% Decrease in Blood Pressure (mm Hg ) 
Systolic Diastolic 
Od 
12 . 0±Q . 0  
1 3  . 5± 1 . 8  
14 . 5±1 . 8  
4 . 5±Q . 4  
0:t0 
Od 
1 3  . 5±0 . 4  
1 5 . 5±1 . 1  
1 5 . 0± 1 . 4  
1 1 . 5± 1 . 8  
9 . 0±1 . 4  
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Two animal� showed response , data of 2 rats showing no activi ty 
not included . Volume ofdtotal dose was always less  than 1 mL . cDissolved in corn oil . Baseline blood pressure af ter recovery from 
anes thesia , 128/ 1 1 5 . 
Table 7 .  
4 1  
Maximum response of 3-( 4-methylphenyl )- 1,2,3,4-oxat riazolium-
5-ola te , 24e.  
24e 
a Dose ( mg/kg) % Decrease in Blood Pressurec (mm Hg) 
Od 
1 
3 
1 0  
1 5  
25 
45  
90 
3 
5 
9 
1 2  
8 
1 
1 
2 
O .Oe 
1 3  . 9±3 . 0  
23 . 5±6 . 2  
28 .Q±8 . 3  
37 . 6±7 . 0 
48 . 1  
5 3 . 0  
7 5 . 3±5 . 4  
�ose given in less  than 1 mL corn oil  by gavage . bNo• o f  rats 
observed . d
CMean change for the no . of  animals  observed, mean arterial 
pres sure .  Control, corn o i l  administered . 
eBaseline blood pressure 
af ter recovery f rom anes thes ia.  
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Table 8.  Hypotensive effect at  2-5  hours of 3-( 4-methylphenyl )-1 , 2 , 3 , 4-
oxa triazolium-5-olate , 24e . 
24e 
a Dose (mg/kg) Nb Time (hr)  % Decreasec in Blood Pressure 
90 2 5 8Q±5. 4  
4 5  5 32 
25 1 5 25 
1 5  8 5d 21±5. 8 1 5 2 0±Q. 2  
aLess  than
b
l mL volume o f  test comgound i n  corn oil by gavage , a 
single dose. No. of rats  observed. Mean decraase in the mean 
arter ial pressure for no . of animals observed. Blood pressure 
returned to pre-inject ion levels and observat ion was terminated. 
Table 9 .  A typical time course for a single dose of 1 5  mg/kg of 
3-( 4-methylphenyl ) -1,2,3,4-oxatriazolium-5-olate, 24e. 
Time
a 
(min) 
Ob 
3 
5 
10 
20 
30 
60 
180 
300 
24e 
Blood Pres sure (mm Hg) 
Systolic Diastolic 
l35c 
125 
115 
103 
8 5  
80 
92 
105 
125 
117 c 
115 
100 
90 
73 
70 
75 
80 
90 
aTime lapsed af ter a single dose for one animal .  bOne hour after 
recovery f rom anes thesia, pentobarbital ( 3 5 mg/kg, ip ) . cBaseline 
blood pressure . 
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the 4-methylphenyl analogue .  
Because the maximum effect at 1 0  mg/kg occurred within thirty 
minutes , this  dose was chosen for single dose studies for seven 
analogues of the 3-aryl- 1 ,2 , 3 , 4-oxatriazolium-S-o lates. Table 1 0  
compares the hypotensive response f o r  a single dose at thirty minutes 
in the rat. In the limited number of observations , the unsubstituted 
compound , 24a , was found to have the greatest activity which was 
approximately twice the activity of the 4-methylphenyl analogue. The 
44 
hypotens ive ef fect of 3-(4-methylphenyl ) - 1 ,2 , 3 , 4-oxatriazolium-S-olate 
when given at a dose of 1 mg/kg was found to equal the hypotensive 
response elicited by hal f  the animals administered clonidine at a dose 
of 0 . 1  mg/kg. Substituents on the aromatic ring resulted in a lowering 
o f  the hypotens ive activity. Thus , optimal steric ,  lipophilic  and 
electronic requirements for the series are met in the unsubstituted 
phenyl mesoionic compound . 
The duration of ef fect of six of the analogues did not follow the 
same ordering as the maximum ef fect at thirty minutes following a 
s ingle dose . The order observed for the duration of the response was :  
The 3-phenyl-� -oxatriazole was tested for its ability to inhibit 
cyclic  3' , S'-monophosphate (cAMP) phosphodiesterase ( PDE ) in an assay 
7 3  described by Klee using bovine heart PDE and 1 �M cAMP. Because of 
poor solubility in the buf fer solution, ethanol was used in a 5% f inal 
concentration to solubilize the test compound. The mesoionic compound 
was f ound to be inactive three times at 60 �M with respect to the 
theophyl line control. 
Table 1 0. Re sponse at 30 minutes of a s ingle 1 0  mg/kg dose of 
A¥-oxatriazolones , 24. 
No. R X 
24a H 4 
24b 4-Cl 4 
24c 3 , 4-C1
2 
3 
24e 4-CH 4 
24d 4-N03 4 
24f 4-0CH; 4 
24g 4-F 4 
24h 2 , 6-Cl2 3 
Clonidine d 
R-C l\ 6
\ 
N-N 
/ \ -N e c-o 
""0/ 
24 
% Decrease a in 
Nb 
Blood Pressure (mm Hg ) 
Systolic Dias tolic 
4 5 1. 7±3. 4 52. 3±3. 2 
2 47. 0±2.0 4 7. 9±1 . 5  
2 3 1. 7±Q. 1 30.9±Q. 6  
1 2  28. 5±8. 1 27. 5±8. 8 
1 24. 8 23. 8 
1 22. 2 20.0 
0 not tes ted 
1 11. 5 8. 3 
4e 7.2±6. 1 7. 9±6. 8 
2f 1 2.0±Q.0 1 3  . 5±Q. 4 
roMc 
61.0 
50. 4 
42. 9 
47.8  
56.2 
51. 6 
42. 9 
0. 44 
0. 44 
�ean dec rease
d
at 30 minutes. 
bNo• animals  given tes t compound. 
�ill imolar conc. Reference compound given at 0.1 mg/kg in corn oil e was obse rved in 2 rats. gtvag e ,  max. ef fect at 2 hours. No ef fect 
The 2 animals  exhib i t ing act ivi ty. 
4S 
by 
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This research has shown that the 3-aryl-l , 2,3 , 4-oxatriazolium-5-
olates pos sess  a moderate hypotensive ef fect in the normotensive male 
white rat .  These orally active compounds were found to have a rapid 
onset of act ion and a long durat ion of hypotensive activity . Data 
obtained in this research does provide a useful basis for further work 
in this area . Further investigation is needed to def ine the s i te and 
mechanism of action at the molecular level . 
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EXPERIMENTAL 
Elemental analyses were performed by Atlantic Microlabs , At lanta ,  
Georgia. The inf rared spectra of the compounds were obtained on a 
Perkin-Elmer Model 2 5 7  s pect rophotometer and a Beckman Acculab 8 
spec t rophotometer. The ult raviolet spectra of the compounds were 
ob tained on a Beckmann Model 25  s pec trophotometer. Mass spectrometer 
f ragmentation pa t tern was obtained by electron-impact technique on the 
Finnegan 4000 series GC/Mass  spectrometer. All melting points were 
determined on a Thomas-Hoover capillary melting point apparatus and are 
uncorrected. TLC were performed on silica gel sheets without 
f luorescent indicator. 
Monopotassium Aminomethanedisulfonate (25 ) .  The methods of von 
Pechmann and Manck58 and Bannard and Ross59 we re used for the 
preparation of 25 . Potass ium me tabisulfite ( 1 1 1  g, 0 . 5 mol)  was 
dis solved in water  (200 mL) at 5 5°C . A solution of potass ium cyanide 
( 6 5  g, 1 . 0 mol)  in water ( 50  mL ) was added to the warm bi sulf ite 
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solution. The solution was heated at 7 5°C for 3 hours . The pH of the 
solution was maintained at 1 0  by the addition of concent rated 
hydrochloric  acid. As the brown solution was cooled to room 
temperature, the pH was adjusted to 2 . 5  with concent rated hydrochloric 
acid. The filtrate was washed twice with water to give 129 g (60%) of 
- 1  - 1  the pure white  inorganic powder. IR(KBr ) : 3 1 60 e m  (NH3 ), 2950 em 
-1 -1 ( CH ),  1 58 5  and 1 5 1 0 em ( NH3 ), 1 260- 1 2 1 0  em ( S03 ) .  
D ipotassium Diazomethanedisulfonate ( 26). The procedure of von 
58 Pechmann and Manck afforded the synthesis  of 26. A slurry of 
monopotass ium aminomethanedisulfonate (23  g, 0. 1 mol) and water ( 34  mL) 
was prepared and cooled to 7°C. Potassium nitrite ( 9. 4  g, 0. 1 1  mol) 
was dissolved in water (20 mL) and cooled to 7°C. Then, all at once 
the ni trite solut ion was added to the slurry wi th s t irring. It was 
removed from the ice bath and the effervescent exothermic react ion was 
allowed to attain a maximum temperature of 4 5°C. Af ter cooling the 
yellow mixture to room temperature, a few drops of a 1 0% potassium 
hydroxide solution were added to pH 9 .  The pure yellow inorganic 
product was collected by filtrat ion, yielding 23. 5 g ( 90% ) .  IR(KBr ) : 
1 - 1  66 \ 
2080 cm- ( C=N=N ), 1 270- 1220 em ( S03 )·  UV(lN-KOH) 
: � max 233 
(E. 47 5 5 ) .  
Tetrapotassium Sulfohyd razonomethane Disulfonic Acid ( 27 ) .  Following 
the procedure of von Pechmann and Mancks8 , potassium metabisulf ite 
( 28.9  g ,  0. 1 3  mol ) and potassium hyd roxide (7. 3  g ,  0. 1 3  mol ) were 
dis solved in water  (80 mL) .  Potass ium diazomethaned isulfonate ( 28 g ,  
0. 1 mol )  was added to the solution. With gentle warming , 
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decolori zation occurred within 1 / 2  hour. Af ter cooling and f iltration 
of the thick mixture , a quantitat ive yield of the white  inorganic 
precipitate was ob tained. IR(KBr ) :  - 1  1260- 1 230 cm ( S03 ) '  
Tripotassium Sulfohydrazonomethanedisulfonate ( 28 ) .  The me thod of von 
58  Pechmann and Manck was used for  the preparat ion of 28.  An aqueous 
s lurry of tetrapotassium sulfohydrazonomethanedisulf onate was made , pH 
14. Glacial acetic  acid was added to pH 6. 5.  Quant itative yields of 
the pure inorganic whi te product were obtained. IR(Nujol) : 
- 1  (NH) , 1 260- 1 230  cm ( S03 ) '  
- 1  3340 cm 
Diazotization of Substituted Anilines. Al l anilines used were 
recrystallized or freshly distilled. To the appropriate aniline ( 1  
mol ) was added concentrated hydrochloric acid ( 2. 3  mol ) .  Enough water 
was added to effect solut ion of the salt. The solut ion was cooled to 
o Oc . An aqueous solut ion of potassium nitrite ( 1 . 1  mol )  was added at a 
rate such that the temp erature always remained between O-soC. 
Diazo tizat ion was comp leted in 1 5  minutes. Granular potas sium acetate 
was added to adjust  to pH 5. 5 while maintaining O- soC. 
Potass ium Hydrazonomethanedisulfonate ( 2 9 ) .  The procedure of von 
Pechmann
s3 a f f orded the synthesis  of �. To an aqueous solution of 
tripotass ium sulfohydrazonomethanedisulfonate (0. 1 mol) was added the 
cold diazobenzene acetate ( 0. 1 5  mol ) .  The pH of the colored 
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eff ervescent mixture was maintained at 5 by the addit ion of granular 
potassium acetate . The react ion was followed by TLC, the product 
f luoresced . The brown tar was f il tered from the desi red aqueous layer 
and washed with hot water twice . The water was removed in vacuo unt il 
precipitat ion began . The colored product was obtained by precipitat ion 
f rom water with ethanol . Yields ranged 5 0-90% depending on react ion 
condi t ions and substi tuent s .  The dry phenyl hydrazone reacted wi th 
concentrated sulfuric acid and ferric chloride to give a violet color. 
TLC : CHC1
3
/MeOH/AcOH=6 / 3 / 1 .  IR( KBr ) : 
- 1  -1 1 545  cm ( C=N ), 1 250- 1220 cm ( S03 ) '  
- 1  - 1  327 0 c m  ( NH), 3020 c m  (CH), 
General Procedure for the Preparat ion � Substituted-3-aryl-l,2,3,4-
oxa triazolium-5-olates ( 2 4 ) .  53  The procedures of  von Pechmann and 
Farrar57 were used in the preparation of 24 . Granular  sodium nitrite 
( 5 5  mmol )  was added to an aqueous solution of po tas s ium arylhydrazono-
methanedisulf onate ( 5 0  mmol) . Nitrosat ion was effected in 30 minutes . 
The aqueous port ion was added to 2N hydrochloric acid ( 300 mL) . The 
forma t ion of the f luorescent product was followed by TLC : CC14 /CHC13 /­
MeOH= 5 / 3 / 1 .  The precipitate was collected in fair yields and 
recrys tallized from methano l .  All compounds exhibited a negat ive 
Liebermann nitroso tes t .  Data for these compounds can be found in 
Table 3 .  
3-Phenyl-l , 2 , 3,4-oxatriazolium-5-olate ( 24a ) . Sodium nitrite ( 3 .8 g ,  
5 5  mmol ) was added to a solution of potass iumphenylhydrazonomethane-
disulfonate ( 17 . 8 5  g, 50  mmol )  in water ( 14 5  mL) . Nitrosation was 
ef fec ted in 30 minutes . The aqueous portion was added to 2N 
hydrochloric acid ( 300 mL) . Production of the f luorescent product from 
the orange mixture was followed by TLC : CCI / 1 / / / 4 CRC 3 MeOH=5 3 1 .  The 
precip i tate was collected af ter 5 hours . Recrystalli zat ion from MeOR 
gave 4 .2 g ( 52% ) o f  24a as yellow needles :  mp 83-84°C , l i t  val .  
5 1  
-1 1 
3060 cm (CH) , 1 785  cm- (C=O) ; NMR (CDC13 ) d 7 . 9-8 . 4  (m ,  5 R ,  
aromatic  protons ) ; UV(EtOR) : A 215 ( €  7286) 265  ( E  9643 ) - mass max ' , 
spec t rum ,  m/e ( relat ive intens ity)  164  (17 ) , 1 3 3  (14) , 105  (23) , 7 7  
( 100) . The Liebermann nitroso tes t was nega t ive . 
Integrated Carbonyl Absorpt ion Intensity. Cell  thickness was 
calculated prior to the experiment .  Spectrograde chloroform was the 
solvent for the tes t  compounds .  Concent rat ions of compounds ranged 
f rom 20-60X10-3 M. The infrared spectra was scanned between 1900-1700 
cm-1 a minimum of 3 t imes per tes t  compound . The method of Ramsay69 
was used to calculate the integrated carbonyl absorption intens ity . 
Pheny lacetate was used as a control , l i terature value7 4  3 .1 ,  found 
3 . 07±0 . 0 5 . See appendix.  
Pharmacology. Eight male Sp rague-Dawley rat s  were adminis tered by 
gavage 3-( 4-methylphenyl )- 1 , 2 , 3 , 4-oxatriazolium-5-olate in dosages of 
50-500 mg/kg dissolved in 0 . 7-0 . 8  mL corn oil . 
60 LD50  was est imated . 
Male Sprague-Dawley rats (250-3 50 g )  were adminis tered pentobarbi tal 
( 3 5  mg/kg , ip) and a femoral artery cannulated . The animal was 
res t rai ned in a supine pos i t ion and the exci s ion area was ba thed in 
normal saline for the durat ion of the experiment . A 10% heparin saline 
solution ( 0 . 01 mL) was injected into  the cannula ted artery 30 seconds 
before recording the blood pressure . Blood pres sure readings were 
taken by Statham transducer interfaced wi th a Grass Model 7 Polygraph . 
After the animal recovered from anesthesia , the blood pressure was 
recorded cont inuous ly for one hour. The tes t compound dissolved in 
0 . 7-0 . 8  mL corn oil was administered by gavage . Blood pressure 
readings were continuously recorded for 30 minutes , then , at various 
time intervals . The animal was sacrificed at the conclusion of each 
experiment . 
S2 
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APPENDIX 
The integrated absorption intensity , A, of an infrared band is  
proportional to the square of the oscillating dipole for the vibration 
of the molecule g iving rise to that band as seen in Equat ion 1 . 7 4  
A 
where N Avagodros numbe r 
c = velocity of l ight 
� 
Q 
Eq . 1 
molecular dipole moment 
normal coordinate 
describing the vibration 
The molecular d ipole wi ll vary with bond stretch ing and bending as a 
resul t of a change in  the total molecular elect ronic conf iguration.  
That i s , d ipole moment f luctuations are dependent on the cont ribution 
of charge separated resonance forms , the nonbonding elect rons and the 
dependence of the nonbonding orbitals on the hybridizat ion. 7 5  
If  the elect ronic s tructure of  a molecule can shift  t o  accommodate 
a change in the length of the carbonyl bond , the value of d1 /d Q f or 
the carbonyl vibration i s  expected to be greater than for a mo lecule 
whe re the bond is  localized . 
Ramsay69 found tha t the true absorpt ion intens ity , A, of an 
inf rared band could be approximated by the integration of a Lorentz 
equation ,  Equat ion 2 .  
( c1 )- 1  In( I / I )� d-.> o 
where �. = adsorption coe f f icient at frequency , v 
c = c oncent rat ion (moles / l i ter) 
I = cell  length ( cm) 
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Eq . 2 
Due to finite  s l i t  widths , the apparent integrated absorption 
intens i t y  was measured . In order to obtain the true integrated 
absorpt ion intensi t y ,  A,  the Ramsay slit  correction factor , K, was 
used . See Equa t ion 3 .  A sample calculation of the integrated carbonyl 
absorpt ion intensity of the 3-phenyl-AV -oxatriazole is seen in Figure 
8 .  
where 
A 
� - 1  
{).J,, = apparent half  band width (cm ) . 2. 
Eq . 3 
Figure 8 .  A sanple calculation of the integrated carbonyl absorption intensity of 3-phenyl- AV �triazole, 24a. 
CrRs 
N-N 
/ \ -
N G) C-O  
""0/ 
24a 
-1 ,'" A = K(el) (InT IT)y t..v", o 
( 1 .57) ( 1 .336)(30 an-I )  
A = -------------------
(5O.306XI0-3 m/1)(0.01051 an) 
where K=1 . 57 
4 -1 -2 A = 1 1 .9)<10 roles -lite� 
or 
A = 1 1 .9 intensity units 
________________________________ �100 ______ __ 
, 
-"" \ 
90 
-
L L -'-
I h = 8.3 an. 
I h/2 = 4.15  an. 
I 
AV�= 30 an. -1 1 '-1 
T = 87.5% 
0 ... -- AV"2 T = 23.0% 
\ 
\ 
ill T IT = 1 .336 
0 
30 
TI 20, ______ __ 
__________________________________ -10 ______ __ 
1 800 
- 1  
em 
� 
REFERENCES 
1 .  Nickerson,  M; Ruedy , J .  In "The Pharmacological Basis  of 
Therapeutics" , 5 th ed . ;  Goodman, L. S . ;  Gilman, A. G . , Eds . ;  
MacMi llan : New York , 1 9 7 5 ;  p 7 1 7 , Chap . 8 .  
56 
2 .  Ha=e r ,  R .  H .  In "Princ iples of Medicinal Chemistry" , Foye , W. O . , 
Ed . ;  Lea and Febige r :  Phi ladelphia , 1 9 7 5 ;  p 3 7 7 . 
3 .  "Hea rt Facts" , Am .  Heart  As soc . ,  1 98 1 .  
4 .  Vander , A. J . ;  Sherman , J .  H . ; Luciano , D .  S .  "Human Physiology , 
The Mechanisms of Body Funct ion" , McGraw-Hil l :  New York , 1 9 7 0 ;  
p 29 7 .  
5 .  Brogden , R .  N . , Ed . " Cardiovascular Drugs" , Univers ity Park Pres s :  
Bal t imore , 19 79 ; Vol .  4 .  
6 .  Bender , A .  D .  In "Top ics in Medicinal Chemi stry" , Rabinowitz , J .  
L . ; Myerson ,  R. M. , Eds . ; Interscience : New York , 1967 ; Vol .  1 ,  
p 1 7 8 .  
7 .  S impson,  F .  O .  In "Cardiovascular Drugs" , Avery , G .  S . , Ed . ;  
University  Park Press : Bal t imore ,  1 9 7 8 ;  p 37 . 
8 .  Taylor , S .  H .  In "Theories and Use of fi-Blockade in Hypertension 
and Angi na" , Roberts ,  R. H . , Ed . ;  Symposia Speciali s t s :  Miami , 
1 9 7 9 ;  p 2 4 0 .  
9 .  DeQuattro , V . ;  Campese ,  V . ;  Antonaccio , M .  J .  I n  "Cardiovascular 
Pharmacology" , Antonaccio , M.  J . , Ed . ;  Raven :  New York , 1 9 7 7 ; 
p 1 98-20 2 .  
10 . Mendlowit z , M. ; Naftchi , N . ; Git low , S .  E . ; Weinreb, H .  L . ; Wolf ,  
R .  L .  Ann .  N . Y .  Acad . Sci . 1960 , 88 , 964 . 
1 1 .  Freis , E .  D .  Circulation 1 9 76 , ll, 589 . 
1 2 .  Heymans , C .  Perspectives BioI . Med . 1 960 , 2, 409 . 
1 3 .  McCubbin ,  J .  W. ; Green , J .  W. ; Page , I .  H .  Cir .  Res . 1 9 56 , �, 205 . 
14 . Clarkson , R .  In "Ant ihypertensive Agents" , Engelhardt ,  E .  L . , Ed . ;  
ACS Symposium Series 2 7 : Washington, D . C . , 1 9 76 ; p 1 9 .  
1 5 .  Moser ,  M . ; Guythe r ,  J .  R . ; Finnerty ,  F . , Jr . ;  Ri chardson, D .  W. ; 
Langf ord , H . ; Perry , H .  M. , Jr . ;  Wood , D .  E . ;  Krishan, I . ;  
Branche , G .  C . , Jr . ;  Smi th , W.  M.  � Am .  Med . Assoc . 1 9 7 7 ,  237 , 
2 5 5 . 
1 6 . Scriabine , A. , Ed . "Pharmacology of Ant ihypertensive Drugs" , 
Raven : New York , 1 9 80 .  
1 7 . Freis , E .  D . ; Rose ,  J .  C . ;  Pantenope , E .  A. ; Higgins , T .  F . ;  
Kel ly , R .  T . ; Schnaper , H .  W. ; Johnson , R .  L .  J .  Clin . Invest .  
1 9 53 , �, 1 285 . - ---
1 8 .  Taraz i ,  R .  C . ; Dus tan , H .  P .  Am .  � Cardiolo.  1 9 7 2 , �, 6 33 .  
1 9 . Wood , A. J . ;  Phelan, E .  L . ; Simpson, F .  O .  Clin.  and Exp. Pharm . 
and Phys . 1 97 5 , �, 297 .  
-- - --
20 . Ear l , J .  C . ; Mackney , A. W .  � Chern . Soc . 1 935 , 399 . 
2 1 . Bake r ,  W; Oll i s , W. D . ; Poole , V .  D .  � Chern . Soc . 1949 , 307 . 
2 2 . Oll i s ,  W .  D . ; Ramsden, C .  A. In "Advances in Heterocyclic 
Chemistry" , Katritzky , A.  R . ; Boulton, A.  J . ,  Eds . ;  Academic 
Pre ss : New York , 1 9 76 ; Vo l .  1 9 .  
23 . Rams den , C .  A .  In "Comprehens ive Organic Chemi s try" , Sammes ,  P .  
G . , Ed . ;  Pergamon Press : London, 1 9 7 9 ;  p 1 1 73 . 
24 . Katr i t zky , A .  R .  Chem . and Ind . 1 955 , 5 2 1 .  
25 . Pott s ,  K .  T . ;  Armbrus ter,  R . ; Houghton, E . ; Kane , J .  � Mass 
Spectrometry 1 9 7 3 , 2, 203 . 
26 . Hanley , R .  N . ; Oll i s ,  W .  D . ; Ramsden ,  C .  A. � Chem . Soc . Chern . 
Comm . 1 9 7 6 , 306 . 
27 . Hanley , R .  N . ; Oll i s , W .  D . ; Rams den , C .  A. � Chem . Soc . Chem . 
Comm . 1 97 6 ,  307 . 
57  
28 . Boyer , J .  H . ; Hernandez ,  J .  A.  � Amer .  Chem . Soc . 1956 , �, 5 1 24 . 
29 . Christophersen, C . ; Treppendahl , S .  Acta Chem . Scand . 19 7 2 ,  8 58 .  
30 . Isukul , E .  A. ; Ranson, R . ; Tillett ,  J .  G .  � � Chem . 1 9 76 , �, 
3040 . 
3 1 .  Talukdar , P .  B . ; Chakraborty , A. Indian � Chem . 1 9 7 3 , ll, 556 . 
32 . Christophersen, C . ; Treppendahl , S .  Acta Chem . Scand . 1 97 1 , �, 
6 2 5 .  
33 . Stewart , F .  H .  C .  Chern . Rev . 1 964 , �, 1 29 .  
34 . Oht a ,  M. ; Kato ,  H .  In "Nonbenzenoid Aromatics" , Snyder , J .  P . , 
Ed . ;  Academic Press : New York , 1 9 69 ; Vol .  1 .  
35 . Greco , C .  V . ; Nyberg , W. H . ; Cheng , C .  C .  J .  Med . Pharm . Chem . 
1962 , 2., 8 6 1 . - --
36 . Kier ,  L .  B . ; Fox, L .  E . ;  Dhawan , D . ; Waters , I .  W. Nature 1962 , 
1 9 5 , 8 1 7 . 
37 . Ackermann, E .  � Pharmazie 1967 , �, 537 . 
38 . Kier ,  L .  B . ; Roche , E .  B .  � Pharm . Sci . 1 967 , 2i, 1 49 .  
39 . Kie r ,  L .  B . ;  Dhawan,  D .  J .  Pharm. Sci . 1962 , 2!, 1 058 . 
40 . Dhawan ,  D . ; Kie r ,  L .  B .  J .  Pharm . Sci . 1 9 64 , 22, 8 3 .  
4 1 . Fregly , M .  J . ;  Kie r ,  L .  B . ; Dhawan,  D .  Toxicol . Appl . Pharmacol . 
1 964 , �, 5 29 . 
42 . Greco , C .  V . ; Tobius , J . ;  Kier ,  L .  B .  J .  Hetero . Chem . 1 967 , i, 
1 6 0 .  
58 
43 . Kie r ,  L. B . ;  AI-Shamma , A. ; Hahn , R. ; Tye ,  A. J .  Pharm. Sci . 1966 , 
�, 1 467 . 
44 . Kier , L .  B . ;  Al-Shamma , A . ; Campbell , D . ; Pat i l ,  P .  H . ; Tye ,  A. 
Nature 1 9 66 , 2 10 ,  7 4 2 . 
4 5 .  Kier , L .  B . ; Keat ing , J .  W .  u . S .  Patent 3 427  3 1 7 , 1 9 6 9 .  
46 . Thoma s ,  T .  L . ; Fedorchuk , M . ; Shetty , B .  V . ; Anderson, F .  E .  J .  
Med .  Chem . 1 9 7 0 , Q, 1 9 6 .  
47 . Ryan , J . ;  Blumentha l ,  H ;  McMahon, F .  Cl in .  Pharm . Ther .  1 9 7 5 , �, 
24 3 . 
48 . Takenada , F . ;  Takeya , N . ; Ishihara , T . ; Inoue , S . ;  Tsutsumi , E . ;  
Nakamura , R . ; Mutsuf iyi , Y . ; Sumie , M .  Jap . � Pharmacol . 1 9 70 , 
20 , 2 5 3 . 
49 . Nitz , R. E .  In "Medicinal Chemistry V, Proceedings of the 5th 
Internat ional Symposium on Medicinal Chemis try" , Mathieu , J . ,  Ed . ;  
Elsevier Scient i f ic : New York , 1 9 7 7 ;  p 233 . 
50 . Masud a ,  K . ; Kami tan i ,  T .  Jap . Patent 7 0 2 1  102 , 1 9 69 ; Chem . Abst r .  
1 970 , 7 3 ,  8 7922f . 
5 1 . Masuda , K . ; Kami tani , T .  Jap . Patent 7020 904 , 1 969 ; Chem . Abst r .  
1 970 , 7 3 ,  8 7 930g . 
52 . Goe t z ,  M . ; Grozinge r ,  K , ; Oliver ,  J .  � Med . Chem . 1 9 7 3 ,  �, 6 7 1 . 
53 . v .  Pechmann , H. Berichte 1 896 , �, 2 1 6 1 . 
59 
54 . Ponzi o ,  G.  Gazzetta 1 9 1 5 ,  �, 1 2 .  
55 . Qui lico , A .  Gaz zetta 1 9 32 , �, 9 1 2 .  
56 . Ponzi o ,  G .  Gazzetta 1933 , �, 4 7 1 .  
57 . Farra r ,  W .  V .  � Chern . Soc . 1 964 , 906 . 
58 . v .  Pechmann , H . ; Manck , Ph . Berichte 1 895 , �, 2374 . 
59 . Bannard , R .  A. B . ; Ross ,  J .  H .  Can . � Chem . 1 954 , 1l, 49 . 
60 . We i l ,  C .  S .  Biometrics  1 9 52 , �, 249 . 
6 1 . Bet t s , R. H . ; Vos s ,  R .  H .  Can .  � Chem . 1 9 70 , �, 2035 . 
62 . Bourne , D .  W .  A. ; Higuchi , T . ; Pitman ,  I .  H .  J .  Pharm . Sci . 1 9 74 , 
�, 865 . 
63 . Meyer , B .  " Sulfur , Energy and Environment" ; Elsevier Scienti f ic : 
Ams terdam ,  1 9 7 7 ;  p 7 7 . 
64 . Her l inger , A. W ' ; Long , T .  V . , I I I .  Inorg . Chem . 1 969 , �, 2 66 1 . 
65 . Meyer ,  B . ;  Peter ,  L . ; Sp i t zer ,  K .  Inorg. Chem . 1 9 7 7 ,  �, 2 7 . 
66 . Young , J .  M.  � Chem . Soc . Perkin ! 1 9 7 4 , 2 54 1 . 
67 . Doughterty , R .  C . ;  Foltz , R. L . ; Kier ,  L .  B .  Tetrahedron 1 970 , �, 
1 989 . 
68 . Christophersen,  C . ; Treppendahl , S .  Acta Chem . Scan . 1 9 7 1 , �, 
6 2 5 . 
70 . Zai t sev , B .  E . ;  Sheinke r ,  Y .  N .  Bull . Acad . Sci .  U . S . S . R . D iv .  
Chem . Sci . 1 962 , 3 7 8 . 
7 1 .  Coburn , R .  A. ; Glennon,  R. A. � Hetero . Chem . 1 9 7 3 , �, 487 . 
7 2 .  McCarthy , A. R . ; Oll i s ,  W .  D . ; Barnes , N .  M. ; Sutton,  L .  E . ; 
Ainsworth ,  C .  � Chem . Soc . (B )  1 969 , 1 1 6 7 . 
7 3 .  Klee , C .  B .  Biochem . 1 9 7 7 , �, 1 0 1 7 . 
74 . Barrow , G .  M .  � Chem . Phys . 1 9 53 , �, 2008 . 
7 5 . Brown , T .  L. Chem . Rev . 1 9 5 8 , 58 , 5 8 1 . 
